Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
ALPS Medical Breakthroughs ETF (SBIO) Eyes +22% Upside to $70

ALPS Medical Breakthroughs ETF (SBIO) Eyes +22% Upside to $70

Key Takeaways

  • The ALPS Medical Breakthroughs ETF (SBIO) is a health-care/biotech ETF, not an individual stock, so the $70 objective is drawn from public market discussion and technical milestones rather than a published analyst consensus.
  • With the fund trading near $57.60, reaching $70 would require a rise of roughly 22%, a substantial move that sits just below the fund's 52-week high of $70.85.
  • The $70 level is a round psychological mark that corresponds closely to the ETF's prior peak, making it a natural benchmark investors are watching.
  • Holdings-level analyst coverage is broadly constructive, with a "Strong Buy"-style tilt across the underlying biotech names, though that sentiment does not translate into an official SBIO price target.
  • Supporting factors include an improving biotech tape, momentum in small- and mid-cap clinical-stage names, and the fund's diversified, low-concentration structure.
  • Key risks are regulatory and clinical-trial setbacks, rising interest rates that pressure long-duration growth assets, and the inherent volatility of small-cap biotechnology.
  • For the latest developments, explore the fund's Major News, Today's Price Move, Forecast, and Earnings pages.
  • Explore Trending AI Robots for AI-driven market analysis.

How the $70 Target Came About

SBIO is an exchange-traded fund that tracks the S-Network Medical Breakthroughs Index, which holds small- and mid-cap U.S. biotech and pharmaceutical companies with at least one drug in Phase II or Phase III FDA clinical trials. Because ETFs generally do not carry their own individual analyst price targets, the $70 figure used here is a fallback objective rooted in public discussion and technical structure rather than a Wall Street consensus.

The fund's 52-week range spans roughly $43.10 to $70.85, meaning $70 sits essentially at the ETF's recent high-water mark. Reclaiming and holding that area is a widely referenced technical objective, and $70 also functions as a clean round-number psychological level. For context, TipRanks derives a much higher holdings-based figure—averaging the analyst price targets of the roughly 100 stocks inside SBIO, which it calculates near $104 to $113. That number reflects deep optimism about the underlying companies but is not a direct, tradable SBIO target and is unrealistically distant for near-term analysis. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

SBIO's Current Position and Path to the Target

SBIO traded around $57.60 in early November, after rebounding from a mid-October dip toward $50. At $57.60, a move to $70 implies about 21.5% upside—a substantial climb for a single ETF position, though well within the historical range of this volatile fund. The fund's assets under management (AUM) total roughly $180–200 million, and it charges a 0.50% expense ratio with no meaningful dividend yield.

The portfolio is diversified across roughly 100 holdings, with the largest positions—including Oruka Therapeutics (ORKA), CG Oncology (CGON), Travere Therapeutics (TVTX), and Dianthus Therapeutics (DNTH)—each representing only around 3% to 4% of assets. That dispersion means no single stock typically drives the fund, but it also means the whole basket moves with broader biotech sentiment.

Factors That Could Help Reach the Target

  • Biotech sector momentum: A favorable tape for clinical-stage and small-cap biotech names tends to lift the entire index, and SBIO has shown sharp rallies when risk appetite improves.
  • FDA catalysts: Positive Phase II/III trial data and regulatory approvals among holdings can re-rate the basket, since the fund is explicitly built around drug-development breakthroughs.
  • Diversified structure: With no single holding dominating, idiosyncratic blowups are partially cushioned, allowing the fund to participate in broad upswings.
  • Constructive analyst sentiment: Holdings-level ratings lean heavily toward Buy, reflecting underlying expectations for clinical and commercial progress.

Risks That Might Block the Way

  • Clinical and regulatory risk: Failed trials or FDA rejections among even a few holdings can weigh on the entire basket.
  • Interest-rate sensitivity: Small-cap, pre-revenue biotechs are long-duration assets; higher rates compress their valuations and dampen appetite for speculative growth.
  • Unprofitable holdings: Many constituents generate little or no revenue, leaving the fund exposed to sentiment shifts and funding-market conditions.
  • Sector rotation: A turn toward defensive or value-oriented sectors could stall momentum even if fundamentals hold.

Technical Levels to Watch

The $70.85 prior high is the clearest resistance zone, with the round $70 level just beneath it acting as a psychological barrier. On the downside, the $50 area—tested in mid-October—served as a notable support level, and the mid-$40s mark the lower bound of the 52-week range. Between roughly $50 and $58, the fund has been trading in a volatile but generally upward-sloping range since its autumn rebound, suggesting the next meaningful test on the upside is the prior peak.

Time Horizon and Key Things to Monitor

Holdings-based analyst targets are typically framed around a 12-month research horizon, though SBIO itself carries no such official horizon. Investors should track clinical-trial readouts and FDA decisions across major holdings, quarterly earnings and guidance from the largest constituents, Federal Reserve interest-rate signals, and any shift in biotech fund flows. ETF-specific items—holdings changes, expense-ratio adjustments, and premium/discount to NAV—also matter for a fund of this size.

AI Daily Buy/Sell Signals

In my own research process, I often rely on Tickeron's AI Daily Buy/Sell Signals to monitor instruments like SBIO. These tools apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical factors. For a volatile name such as this ETF, the signals can help identify trend changes more efficiently than manual review alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SBIO

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


SBIO's RSI Indicator climbs out of oversold territory

The RSI Oscillator for SBIO moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on SBIO as a result. In 75 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on October 20, 2026. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in 46 of 51 cases over the following month. The odds of a continued upward trend are 90%.

Following a +9.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in 277 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

The Aroon Indicator entered an Uptrend today. In 211 of 230 cases where SBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 63 cases where SBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

SBIO moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

SBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF (SBIO) ETF is 2.08B. The market cap for tickers in the group ranges from 63.25M to 6.81B. ORKA holds the highest valuation in this group at 6.81B. The lowest valued company is TENX at 63.25M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was -0%. For the same ETF, the average monthly price growth was 9%, and the average quarterly price growth was 4%. DCTH experienced the highest price growth at 38%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was -12%. For the same stocks of the ETF, the average monthly volume growth was -14% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 41
Price Growth Rating: 58
SMR Rating: 93
Profit Risk Rating: 87
Seasonality Score: 5 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
Alphabet (GOOGL) fell roughly 15.3% over the last 30 days, sliding from about $349.22 to $295.77, driven primarily by a post-earnings selloff. The decline followed Alphabet's Q3 2026 results, when earnings per share of $2.12 badly missed the $3.02 consensus estimate.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
ALPS Medical Breakthroughs ETF (SBIO) Eyes +22% Upside to $70